Sales & Earnings

In this week's podcast edition of Five Must-Know Things: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs.

BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.

The Merck & Co vaccine for human papillomavirus Gardasil, along with Johnson & Johnson’s Darzalex for multiple myeloma, entered the ranks of the top 10 best-selling drugs globally in the second quarter. There was no product for COVID-19 in the line-up for the first time since 2020.

Join Scrip's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.

CSL’s evolution from plasma fractioneer to biotech has reached the extent of an approved gene therapy just as gene therapy commercialization faces challenges. Meanwhile, in the post-pandemic inflationary environment, CSL’s margins in its biggest blood products division are impacted by increased donor fees and higher labor costs.

The commercial and clinical successes of Lilly and Novo's respective GLP-1 receptor agonists provided an explosive finale to the second-quarter earnings season but also raised questions on reimbursement.

Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.

The Swedish biotech’s immunoglobulin A nephropathy therapy Tarpeyo is still selling well but “market access friction” is slowing growth. As US regulators grant a priority review to its data package for full approval, Calliditas’s prospects look promising.

Rexulti launch in agitation associated with Alzheimer’s disease is under way with a branded DTC marketing campaign planned for fall.

A US FDA tentative approval for Aurobindo’s dolutegravir combination generic for children should increase access under the PEPFAR program and aid sales. On a Q1 earnings call, renewed efforts to restructure Eugia, biosimilar launch plans and fallouts of oral drug shortages and damage to Pfizer’s US injectables warehouse were discussed

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Sun stays “tentative” about a large exposure in the biosimilars segment while also outlining its approach to commercialize some diverse pipeline assets including an early stage GLP-1 receptor agonist.

In this week's podcast edition of Five Must-Know Things: Wegovy’s solid new trial results; Lilly’s sales swing back; nothing off the table for new Bayer boss; new compliance crackdown in China; and McKinsey on AI.

While not direct competitors in all therapeutic areas, Pfizer’s and Merck’s sales offered some stark contrasts in the second quarter.

The company reported 3,800 ALS patients on drug, a figure that came in slightly below some analyst estimates but which suggested discontinuation rates consistent with the pivotal trial.

The Danish firm’s Q2 sales fell short of expectations due to poor rare disease and diabetes performance, but a potentially billion-dollar buy of Inversago stole attention as observers highlighted the historical risks of targeting the cannabinoid-1 receptor.